WSA
GEVA

Wall Street Associates’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Wall Street Associates’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-12,428
Closed -$1.21M – 375
2015
Q1 		$1.21M Sell
12,428
-300
-2% -$31.8K 0.11% 193
2014
Q4 		$1.18M Buy
+12,728
New +$1M 0.11% 187

Wall Street Associates's GEVA Position: Q2 2015 in Review

Wall Street Associates sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 12,428 shares — an estimated $1.21M sold.

Wall Street Associates first reported a position in GEVA in Q4 2014 and held it in 2 quarters. The position peaked at $1.21M in Q1 2015. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

  • Wall Street Associates reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
  • Wall Street Associates sold 12,428 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $1.21M.
  • Wall Street Associates first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q4 2014 and held it in 2 quarters.
  • Wall Street Associates's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $1.21M in Q1 2015.
  • 0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on Wall Street Associates's 13F filing for Q2 2015, filed 13 Aug 2015.